MorphoSys AG is a biopharmaceutical company specializing in the discovery, development and commercialization of innovative antibody-based therapies. Founded in 1992 and headquartered in Planegg, Germany, MorphoSys has built a robust platform for antibody generation and engineering, known as the MorphoSys Antibody Technology (HuCAL). This proprietary technology has enabled the company to identify and optimize novel therapeutic candidates across a range of disease areas, including oncology, inflammation and autoimmune disorders.
The company’s pipeline features both internally developed products and partnered programs. Among its lead products is Monjuvi (tafasitamab-cxix), approved in the United States and Europe for the treatment of certain forms of relapsed or refractory diffuse large B-cell lymphoma. MorphoSys also has several clinical-stage candidates, such as pelabresib in collaboration with Incyte, targeting myelofibrosis, and other preclinical antibody programs addressing solid tumors and hematological malignancies. In addition to its in-house development efforts, MorphoSys maintains strategic collaborations with pharmaceutical partners including GSK, Janssen and Novartis, leveraging its HuCAL technology to co-develop and license therapeutic antibodies.
With operations spanning Europe and North America, MorphoSys maintains research facilities in Munich and Boston, as well as a U.S. subsidiary responsible for clinical development and commercialization activities. The company’s leadership team combines expertise in biotechnology, clinical research and commercial strategy. Since August 2022, Jean-Paul Kress has served as Chief Executive Officer, guiding MorphoSys through late-stage clinical trials and market rollouts. Under his stewardship, the firm continues to expand its pipeline, explore new therapeutic targets and pursue partnerships that accelerate the delivery of novel treatments to patients worldwide.
AI Generated. May Contain Errors.
